Health Tip: Prevent Traveler's Diarrhea

'modId':'mediasocialchromefriends','isPreLoad':0,'enableMediaTabEvent':0,'pageSize':12,'numFriends':null,'notificationCount':0,'property':'News','learnMorePath':'/activity-learn-more/','friendbarNotification':'1','friendbarRollup':'0','moduleConf':YAHOO.Media.Facebook.ModuleConf,'friendIdList':

View the Original article

Study Says Priobiotics Ward Off Diarrhea After Antibiotics

This story comes from the Yahoo! Contributor Network, where individuals publish their unique perspectives on some of the world’s most popular websites.Do you have a story to tell? Become a Yahoo! contributor

FIRST PERSON

View the Original article

Probiotic Products May Prevent Antibiotic-Linked Diarrhea

HealthDay – 4 hrs ago TUESDAY, May 8 (HealthDay News) -- Consuming probiotic-rich foods may decrease the risk of diarrhea for patients who are taking antibiotics, a new study suggests.

Probiotics are live microorganisms that are found naturally in foods such as yogurt and are believed to provide health benefits.

About 30 percent of patients who take antibiotics will experience diarrhea because the drugs disrupt gastrointestinal microbes, and diarrhea is one of the main reasons people don't adhere to antibiotic treatment.

"Diarrhea is a common problem in patients receiving antibiotic therapy and may limit their use," said Dr. David Bernstein, chief of hepatology at North Shore University Hospital in Manhasset, N.Y. Bernstein was not involved in the new study.

"While these antibiotics treat the underlying infection, they also alter the normal gut

View the Original article

FDA extends review for Salix diarrhea drug

Reuters – Mon, Apr 30, 2012 (Reuters) - Salix Pharmaceuticals Ltd said U.S. health regulators have extended the review date by three months for its experimental pill for HIV therapy-related diarrhea.

The U.S. Food and Drug Administration was to review the drug, crofelemer, on June 5.

The FDA has notified Salix that it requires additional time for a full review but did not seek any additional studies, the company said in a statement.

Salix holds the North American and European rights to the drug.

India's Glenmark Pharmaceuticals Ltd holds the rights to sell the drug in 140 other countries but is in arbitration to retain them after initial developer U.S.-based Napo Pharamaceuticals Inc terminated their agreement in November.

Shares of Salix Pharmaceuticals were trading down about 3 percent at $49.28 on Monday afternoon trade on the Nasdaq.

(Reporting by Balaji Sridharan in Bangalore; Editing by Saumyadeb Chakrabarty)

View the Original article